Companies › iVascular S.L.U.
2 active drug programs in 2 registered trials: 2 Phase 3; Cardiovascular; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| 1-month DAPT Dual antiplatelet therapy (acetylsalicylic acid + prasugrel or ticagrelor) for 1 month, fo | P2RY12, TBXA2R | Phase 3 | Coronary Artery Disease | Jan 2027 |
| Angiolite Sirolimus-eluting stent with thin-strut cobalt-chromium, open-cell design, durable biostab | MTOR | Phase 3 | Coronary Artery Disease | Jan 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05952206 | Angiolite | Phase 3 | Coronary Artery Disease | Cardiovascular | Jan 2027 |
| NCT05952206 | 1-month DAPT | Phase 3 | Coronary Artery Disease | Cardiovascular | Jan 2027 |
Trust Bio-sonics Liquidia Technologies EVD Pharmacy and Medical Company Pulmovant EBI Anti Sepsis
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.